As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population. Read more
With only 5% of patients stopping treatment due to treatment-related adverse events, lead author Yuankai Shi, MD, says glecirasib may help improve patient compliance with oral therapy. Read more
In a two-part commentary, Dr. Ke-Neng Chen discusses how surgeons must adjust in light of recent clinical trials, beginning with a discussion of the challenges of TNM staging. Read more
As thoracic surgery in the management of NSCLC evolves, Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach. Read more
In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions. Read more
Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed. Read more
Drs. Laila Roisman and Nir Peled envision a future where artificial intelligence elevates personalized medicine in ways once thought impossible. Read more
Drs. Christi M.J. Steendam and Sushil K. Badrising review studies comparing outcomes of various treatment regimens in the search for the best-performing approach. Read more
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress. Read more
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress. Read more